These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2067 related items for PubMed ID: 19322513

  • 21. GH and mortality in acromegaly.
    Sheppard MC.
    J Endocrinol Invest; 2005; 28(11 Suppl International):75-7. PubMed ID: 16625851
    [Abstract] [Full Text] [Related]

  • 22. Impact of treatment with recombinant human GH and IGF-I on visceral adipose tissue and glucose homeostasis in adults.
    Yuen KC, Dunger DB.
    Growth Horm IGF Res; 2006 Jul; 16 Suppl A():S55-61. PubMed ID: 16624605
    [Abstract] [Full Text] [Related]

  • 23. Oral glucose tolerance test in Italian overweight/obese children and adolescents results in a very high prevalence of impaired fasting glycaemia, but not of diabetes.
    Cambuli VM, Incani M, Pilia S, Congiu T, Cavallo MG, Cossu E, Sentinelli F, Mariotti S, Loche S, Baroni MG.
    Diabetes Metab Res Rev; 2009 Sep; 25(6):528-34. PubMed ID: 19496065
    [Abstract] [Full Text] [Related]

  • 24. Hyperglycemia and antipsychotic medications.
    Haupt DW, Newcomer JW.
    J Clin Psychiatry; 2001 Sep; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
    [Abstract] [Full Text] [Related]

  • 25. Impact of 5 years of growth hormone replacement therapy on cardiovascular risk factors in growth hormone-deficient adults.
    Cenci MC, Conceição FL, Soares DV, Spina LD, Brasil RR, Lobo PM, Michmacher E, Vaisman M.
    Metabolism; 2008 Jan; 57(1):121-9. PubMed ID: 18078869
    [Abstract] [Full Text] [Related]

  • 26. Glucose metabolism in patients with essential hypertension.
    García-Puig J, Ruilope LM, Luque M, Fernández J, Ortega R, Dal-Ré R, AVANT Study Group Investigators.
    Am J Med; 2006 Apr; 119(4):318-26. PubMed ID: 16564774
    [Abstract] [Full Text] [Related]

  • 27. Visceral obesity, impaired glucose tolerance, metabolic syndrome, and growth hormone therapy.
    Attallah H, Friedlander AL, Hoffman AR.
    Growth Horm IGF Res; 2006 Jul; 16 Suppl A():S62-7. PubMed ID: 16624603
    [Abstract] [Full Text] [Related]

  • 28. Dynamic tests and basal values for defining active acromegaly.
    Tzanela M.
    Neuroendocrinology; 2006 Jul; 83(3-4):200-4. PubMed ID: 17047383
    [Abstract] [Full Text] [Related]

  • 29. Biochemical evidence supporting the Cortina criteria.
    von Werder K.
    J Endocrinol Invest; 2005 Jul; 28(11 Suppl International):81-3. PubMed ID: 16625853
    [Abstract] [Full Text] [Related]

  • 30. 11beta-hydroxysteroid dehydrogenase activity in acromegalic patients with normal or impaired carbohydrate metabolism.
    Mondok A, Varga I, Glaz E, Szucs N, Tóth M, Patocs A, Beko G, Racz K.
    Steroids; 2009 Sep; 74(9):725-9. PubMed ID: 19540999
    [Abstract] [Full Text] [Related]

  • 31. Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients.
    Resmini E, Barreca A, Ferone D, Giusti M, Sidoti M, Minuto F.
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):294-7. PubMed ID: 16117816
    [Abstract] [Full Text] [Related]

  • 32. The GH-IGF-I axis and the cardiovascular system: clinical implications.
    Colao A.
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):347-58. PubMed ID: 18462260
    [Abstract] [Full Text] [Related]

  • 33. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.
    Minuto F, Resmini E, Boschetti M, Arvigo M, Sormani MP, Giusti M, Ferone D, Barreca A.
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):138-44. PubMed ID: 15212656
    [Abstract] [Full Text] [Related]

  • 34. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
    Reaven GM.
    Panminerva Med; 2005 Dec; 47(4):201-10. PubMed ID: 16489319
    [Abstract] [Full Text] [Related]

  • 35. [Epidemiology of diabetes mellitus: prevalence, incidence, pathogenesis, and prognosis].
    Janka HU, Michaelis D.
    Z Arztl Fortbild Qualitatssich; 2002 Mar; 96(3):159-65. PubMed ID: 12017759
    [Abstract] [Full Text] [Related]

  • 36. [Insulin resistance in pituitary, thyroid, and adrenal diseases].
    Iitaka M, Katayama S.
    Nihon Rinsho; 2000 Feb; 58(2):451-5. PubMed ID: 10707575
    [Abstract] [Full Text] [Related]

  • 37. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Protonotariou A, Lytras A.
    Neuroendocrinology; 2006 Feb; 83(3-4):249-57. PubMed ID: 17047390
    [Abstract] [Full Text] [Related]

  • 38. Type 2 diabetes and the polycystic ovary syndrome.
    Pelusi B, Gambineri A, Pasquali R.
    Minerva Ginecol; 2004 Feb; 56(1):41-51. PubMed ID: 14973409
    [Abstract] [Full Text] [Related]

  • 39. Insulin resistance in a rural Maori community.
    Tipene-Leach D, Pahau H, Joseph N, Coppell K, McAuley K, Booker C, Williams S, Mann J.
    N Z Med J; 2004 Dec 17; 117(1207):U1208. PubMed ID: 15608803
    [Abstract] [Full Text] [Related]

  • 40. Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults.
    Yuen KC, Dunger DB.
    Diabetes Obes Metab; 2007 Jan 17; 9(1):11-22. PubMed ID: 17199714
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 104.